Brief: Dr Reddy's Launches India's First DCGI-Approved Semaglutide Injection Obeda For Type 2 Diabetes

Dr. Reddy's Laboratories

21/03/2026 02:13

March 20 (Reuters) - Dr Reddy's Laboratories Ltd REDY.NS:

DR REDDY'S  - LAUNCHES INDIA'S FIRST DCGI-APPROVED SEMAGLUTIDE INJECTION OBEDA FOR TYPE 2 DIABETES

DR REDDY'S  - EACH OBEDA PEN DELIVERS 4 WEEKLY DOSES; COST TO PATIENT 4,200 RUPEES PER MONTH

DR REDDY'S : AIMS TO INTRODUCE GENERIC SEMAGLUTIDE IN SEVERAL COUNTRIES AS PART OF ITS PHASE-1 LAUNCH

Source text: ID:nBSE9v3Gz1

Further company coverage: REDY.NS

 ((Reuters.Briefs@thomsonreuters.com;))